NewsFeeder
Headline News
Athira Pharma to raise up to $170 million in IPO
Athira Pharma Inc. set terms Monday for its initial public offering, in which the the biopharmaceutical company focused on developing treatment for neurological diseases, including Alzheimer's disease, can raise up to $170 million and be valued at up to about $489.5 million. The company is offering 10 million shares in the IPO, which is expected to price at $15 to $17. Athira's stock is expected to trade on the Nasdaq under the ticker symbol "ATHA." The company will have 28.8 million shares outstanding after the IPO. Goldman Sachs, Jefferies and Stifel Nicolaus and JMP are the lead underwriters. For the six months ended June 30, the company recorded a net loss of $3.8 million on no revenue, after a loss of $2.7 million on no revenue in the same period a year ago. The company is looking to go public at a time that the Renaissance IPO ETF has rallied 27.1% over the past three months and the S&P 500 has gained 9.9%.
https://finance.yahoo.com/m/c8eccf3...2/athira-pharma-to-raise-up-to.html?.tsrc=rss
Athira Pharma Inc. set terms Monday for its initial public offering, in which the the biopharmaceutical company focused on developing treatment for neurological diseases, including Alzheimer's disease, can raise up to $170 million and be valued at up to about $489.5 million. The company is offering 10 million shares in the IPO, which is expected to price at $15 to $17. Athira's stock is expected to trade on the Nasdaq under the ticker symbol "ATHA." The company will have 28.8 million shares outstanding after the IPO. Goldman Sachs, Jefferies and Stifel Nicolaus and JMP are the lead underwriters. For the six months ended June 30, the company recorded a net loss of $3.8 million on no revenue, after a loss of $2.7 million on no revenue in the same period a year ago. The company is looking to go public at a time that the Renaissance IPO ETF has rallied 27.1% over the past three months and the S&P 500 has gained 9.9%.
https://finance.yahoo.com/m/c8eccf3...2/athira-pharma-to-raise-up-to.html?.tsrc=rss
